TICKERNERD
Menu
CPIXCPIXHealthcare · Drug Manufacturers - Specialty & Generic

CPIX Stock Forecast: Cumberland Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$7.65
+2.00% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 22 Aug 2026 — inside the top quartile.

Market cap
$114.6M
Ticker Nerd rank
85 / 100
Median analyst target
—
Analysts covering
1
Total return, dividends reinvested
1W
−1.8%
1M
+16.2%
YTD
+129.2%
1Y
+181.5%
From 52W high
−3.9%
From 52W low
+380.0%
$1.59
$7.96
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CPIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cumberland Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
85 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
95
Accruals
94
Issuance
89
Quality
85
Size
74
Value
68
Volatility
44
Revisions
25
Growth
22

Momentum (95): The shares have been drifting up relative to others.

Growth (22): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CPIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CPIX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26CPIX

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Dec 2019B. RileyMaintainsBuy—
3 Dec 2019B. Riley SecuritiesMaintainsBuy$9.00 → $9.75
18 Nov 2019B. Riley FBRMaintainsBuy—
18 Nov 2019B. Riley SecuritiesMaintainsBuy—
17 Aug 2018B. Riley FBRMaintainsBuy—
17 Aug 2018B. Riley SecuritiesMaintainsBuy—
5 May 2018B. Riley FBRInitiatesBuy—
17 Apr 2018B. Riley FBRInitiatesBuy—
17 Apr 2018B. Riley SecuritiesInitiatesBuy—
10 Apr 2013UBSMaintainsNeutral—
12 Nov 2012UBSMaintainsNeutral—
9 Nov 2012Wells FargoDowngradeMarket Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CPIX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CPIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Cumberland Pharmaceuticals, Inc. (CPIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−40.1×

Cheaper than 98% of US stocks

Price / sales
2.6×

Cheaper than 47% of US stocks

Price / book
6.6×

Cheaper than 16% of US stocks

EV / EBITDA
105.0×

Cheaper than 2% of US stocks

Growth & margins
Revenue growth (YoY)
−56.3%

Higher than 5% of US stocks

Earnings growth (YoY)
−18.8%

Higher than 20% of US stocks

Gross margin
78.8%

Higher than 90% of US stocks

Operating margin
−1898.7%

Higher than 4% of US stocks

Net margin
−24.6%

Higher than 14% of US stocks

Returns & dividend
Return on equity
−14.4%

Higher than 34% of US stocks

Return on assets
−2.9%

Higher than 35% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CPIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
CPIXCumberland Pharmaceuticals, Inc.$114.6M
85
BGMBGM Group Ltd.$110.3M
33
ADCTADC Therapeutics SA$123.5M
73
LFCRLifecore Biomedical, Inc.$170.1M
4
OGIOrganigram Global, Inc.$177.3M
40
CTORCitius Oncology, Inc.$69.2M
15
DERMJourney Medical Corp.$211.8M
67

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cumberland Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CPIX news & analysis

Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity

Seeking Alpha · 13 Aug 2026neutral

Cumberland Pharmaceuticals sold a $100M asset to Apotex, funded operations and paid a special dividend, while pivoting from a commercial-stage pharma to a pre-revenue Phase 2 biotech focused on rare diseases, retaining four late-stage ifetroban-based programs.

Why it matters — A CPIX watcher would care because the company's transformation into a pre-revenue biotech with a single-drug pipeline creates both potential upside from high-value indications and significant risk without current product sales.

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

The Q2 2026 earnings call transcript for Cumberland Pharmaceuticals Inc. (CPIX) was published on Seeking Alpha. The transcript covers the company's second-quarter 2026 earnings discussion.

Why it matters — A CPIX watcher would care because the transcript offers insight into the company's latest quarterly performance and management commentary.

Cumberland Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 4 Aug 2026negative

Cumberland Pharmaceuticals reported a second-quarter operating loss of $3.1 million as it prepares to transition from a commercial-stage specialty pharmaceutical company into an innovation-focused biopharmaceutical business after selling its U.S. branded commercial portfolio to Apotex Health.

Why it matters — A CPIX watcher would care because the operating loss marks a significant financial milestone as the company undergoes a major strategic transformation following the sale of its core commercial portfolio.

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

PRNewsWire · 4 Aug 2026positive

Cumberland Pharmaceuticals reported its Q2 2026 financial results and provided a company update following the closing of its $100 million Strategic Transaction with Apotex Health. The update also noted that a special shareholder dividend has been funded and that the company is advancing its late-stage clinical pipeline.

Why it matters — A CPIX watcher would care because the closed strategic transaction, funded special dividend, and advancing late-stage clinical pipeline reflect tangible milestones for the company's near-term financial and development outlook.

Possible Generic Drug Tariffs and 2 Microcaps

Zacks Investment Research · 31 July 2026neutral

A Zacks Investment Research article notes that possible tariffs on generic drugs could impact Cumberland Pharmaceuticals (CPIX), along with another microcap, ELTP.

Why it matters — CPIX investors may want to monitor generic drug tariff developments, as such policy changes could affect the company's operations or competitive position.

FAQ

Frequently asked questions about CPIX stock

Is CPIX stock a buy right now?

Of the 1 analysts covering Cumberland Pharmaceuticals, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cumberland Pharmaceuticals, Inc. 85 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CPIX?

As at 22 Aug 2026, Cumberland Pharmaceuticals, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).

What is the CPIX stock forecast for 2030?

No analyst covering Cumberland Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CPIX are extrapolating price history, which says nothing about the business.

How has CPIX stock performed over the past year?

Cumberland Pharmaceuticals, Inc. returned +181.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cumberland Pharmaceuticals, Inc. do?

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of innovative prescription products aimed at improving patient care.

What is the latest news on CPIX?

The most recent item we track (Seeking Alpha, 13 Aug 2026): "Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity". Cumberland Pharmaceuticals sold a $100M asset to Apotex, funded operations and paid a special dividend, while pivoting from a commercial-stage pharma to a pre-revenue Phase 2 biotech focused on rare diseases, retaining four late-stage ifetroban-based programs.

Company

About Cumberland Pharmaceuticals, Inc.

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of innovative prescription products aimed at improving patient care. The company primarily operates in the healthcare sector, offering a portfolio of niche-market prescription products that address significant medical needs. Cumberland's product range includes treatments for hospital acute care settings, gastroenterology, and oncology, catering to specific therapeutic segments. Founded in 1999 and headquartered in Nashville, Tennessee, the company leverages a network of direct salesforce alongside partnerships with other health care providers and distributors to ensure broad product availability across the United States market. Cumberland Pharmaceuticals plays a critical role in the healthcare industry by providing essential medications that enhance treatment outcomes and address unmet medical needs. Its commitment to expanding therapeutic options and improving patient access to specialized treatments underscores its significance in the pharmaceutical market.

CEO Mr. A. J. Kazimi MBA · 88 employees · United States · https://www.cumberlandpharma.com